Therapeutics (TGTX) 2025 Earnings Outlook for Investors
TG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
Not all investors can use a backdoor Roth. This intro clarifies eligibility and the basic implementation steps.
27,669 articlesTG Therapeutics faces a pivotal year as it closes 2025 with a tighter focus on its flagship therapeutics portfolio an...
A lithium-extraction startup says its new method triples recovery while shortening timelines, accelerating toward com...
Owlet's Q4 2025 results reveal a company balancing growth with a path toward profitability. This article disentangles...
Geopolitical conflicts are upending the classic playbook for U.S. stocks. The S&P 500 has not followed the traditiona...
Oil prices rose as the IEA deployed an historic stock draw, yet Carlyle Group’s Currie argued there’s policy response...
As 2026 AI demand shifts, investors weigh TSMC and AMD on who can sustain capacity, pricing power, and growth. This p...
Oakmark Select adds to discounted stocks in Q4, signaling a shift toward durable earnings as volatility persists. Nyg...
Joe Kent, a former Army Special Forces officer and two-time congressional candidate, quit today from a top counterter...
A fresh ETF blends SCHD with an options overlay to target about twice the underlying yield. The approach promises hig...
A crisis-focused charity is pivoting to support TSA officers unpaid during a partial government shutdown. The effort ...
Silver miners surged 124% over the past year and platinum climbed 89%, but volatility has risen. Investors face a cle...
By 2026, European DST policies are still pressing issues for tech giants and online platforms. This guide breaks down...